Published in Front Immunol on March 06, 2017
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature (2008) 14.99
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 14.63
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol (1988) 12.52
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2002) 11.87
IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2002) 11.22
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 6.16
Lambda interferon inhibits hepatitis B and C virus replication. J Virol (2005) 5.47
A new classification for HIV-1. Nature (1998) 5.30
IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog (2008) 4.70
Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol (2006) 4.21
An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol (2008) 3.75
Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood (2008) 2.96
Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature (2013) 2.79
Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem (2004) 2.55
MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature (2013) 2.40
The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe (2013) 2.39
Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog (2008) 2.38
Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol (2010) 2.28
Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine (2005) 2.27
IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol (2005) 2.05
Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Stat Med (2004) 2.04
Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol (2009) 1.88
Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun (2009) 1.81
IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res (2006) 1.77
Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol (2009) 1.74
Crystal structure of the IL-10/IL-10R1 complex reveals a shared receptor binding site. Immunity (2001) 1.64
Methamphetamine enhances HIV infection of macrophages. Am J Pathol (2008) 1.60
Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun (2007) 1.60
Infection of cord blood monocyte-derived macrophages with human immunodeficiency virus type 1. J Virol (1992) 1.36
2004: which HIV-1 drug resistance mutations are common in clinical practice? AIDS Rev (2004) 1.29
A critical function of toll-like receptor-3 in the induction of anti-human immunodeficiency virus activities in macrophages. Immunology (2010) 1.27
Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors (2009) 1.26
Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun (2006) 1.24
HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. Blood (2012) 1.21
Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci (2008) 1.19
CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes. Hepatology (2009) 1.16
Antiviral effect of interferon lambda against West Nile virus. Antiviral Res (2009) 1.12
Interferon-lambda as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res (2010) 1.10
Inhibition of anti-HIV microRNA expression: a mechanism for opioid-mediated enhancement of HIV infection of monocytes. Am J Pathol (2010) 1.08
Activation of toll-like receptor-3 induces interferon-lambda expression in human neuronal cells. Neuroscience (2009) 1.07
Alcohol potentiates HIV-1 infection of human blood mononuclear phagocytes. Alcohol Clin Exp Res (2002) 1.06
HIV entry inhibitors and their potential in HIV therapy. Med Res Rev (2009) 1.04
Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol (2011) 1.04
Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis (2001) 1.04
Novel interferons. Nat Immunol (2003) 1.04
IFN-λ3 inhibits HIV infection of macrophages through the JAK-STAT pathway. PLoS One (2012) 1.02
Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons. Glia (2010) 1.02
Interferon-λ in HCV Infection and Therapy. Viruses (2010) 0.98
Interferon-λ in the context of viral infections: production, response and therapeutic implications. J Innate Immun (2014) 0.96
Resistance issues with new nucleoside/nucleotide backbone options. J Acquir Immune Defic Syndr (2004) 0.92
Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages. Antimicrob Agents Chemother (2012) 0.89
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Mol Cancer Ther (2010) 0.88
Antiviral activity of type I interferons and interleukins 29 and 28a (type III interferons) against Apeu virus. Antiviral Res (2008) 0.87
Tetherin and its viral antagonists. J Neuroimmune Pharmacol (2011) 0.87
IFN-λ inhibits HIV-1 integration and post-transcriptional events in vitro, but there is only limited in vivo repression of viral production. Antiviral Res (2012) 0.85
Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic. J Clin Transl Hepatol (2013) 0.79
Interferon lambda inhibits dengue virus replication in epithelial cells. Virol J (2015) 0.79
Inhibition of HIV Expression and Integration in Macrophages by Methylglyoxal-Bis-Guanylhydrazone. J Virol (2015) 0.78
Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. J Interferon Cytokine Res (2016) 0.78
Association of interferon lambda-1 with herpes simplex viruses-1 and -2, Epstein-Barr virus, and human cytomegalovirus in chronic periodontitis. J Investig Clin Dent (2015) 0.76
Comparison of antiviral activity of lambda-interferons against HIV replication in macrophages. J Interferon Cytokine Res (2014) 0.76
Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C. J Interferon Cytokine Res (2015) 0.76